Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1

Moonnoh R. Lee, David J. Hinton, Jinhua Wu, Prasanna K. Mishra, John D Port, Slobodan I Macura, Doo Sup Choi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Acamprosate is clinically used to treat alcoholism. However, the precise molecular functionality of acamprosate in the central nervous system remains unclear, although it is known to antagonize glutamate action in the brain. Since elevated glutamate signaling, especially in the nucleus accumbens (NAc), is implicated in several aspects of alcoholism, we utilized mice lacking type 1 equilibrative nucleoside transporter (ENT1), which exhibit increased glutamate levels in the NAc as well as increased ethanol drinking behaviors. We found that acamprosate significantly reduced ethanol drinking of mice lacking ENT1 (ENT1 -/-) while having no such effect in wild-type littermates. We then analyzed the basal and acamprosate-treated accumbal metabolite profiles of ENT1 -/- and wild-type mice using in vivo 16.4T proton magnetic resonance spectroscopy (MRS). Our data show that basal glutamate+glutamine (Glx), glutamate, glutamine and N-acetylaspartatic acid (NAA) levels are increased in the nucleus accumbens (NAc) of ENT1 -/- compared to wild-type mice. We then found that acamprosate treatment significantly reduced Glx and glutamine levels while increasing taurine levels in the NAc of only ENT1 -/- compared to their saline-treated group while normalizing other metabolite compared to wild-type mice. This study will be useful in the understanding of the molecular basis of acamprosate in the brain.

Original languageEnglish (US)
Pages (from-to)90-95
Number of pages6
JournalNeuroscience Letters
Volume490
Issue number2
DOIs
StatePublished - Feb 25 2011

Fingerprint

Drinking Behavior
Ethanol
Nucleus Accumbens
Glutamic Acid
Glutamine
Alcoholism
Taurine
Brain
Drinking
acamprosate
Central Nervous System
Acids

Keywords

  • Acamprosate
  • Alcoholism
  • ENT1
  • Glutamate
  • In vivo MRS
  • Taurine

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1. / Lee, Moonnoh R.; Hinton, David J.; Wu, Jinhua; Mishra, Prasanna K.; Port, John D; Macura, Slobodan I; Choi, Doo Sup.

In: Neuroscience Letters, Vol. 490, No. 2, 25.02.2011, p. 90-95.

Research output: Contribution to journalArticle

@article{885b7756b92144a69bb1e836720b4d82,
title = "Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1",
abstract = "Acamprosate is clinically used to treat alcoholism. However, the precise molecular functionality of acamprosate in the central nervous system remains unclear, although it is known to antagonize glutamate action in the brain. Since elevated glutamate signaling, especially in the nucleus accumbens (NAc), is implicated in several aspects of alcoholism, we utilized mice lacking type 1 equilibrative nucleoside transporter (ENT1), which exhibit increased glutamate levels in the NAc as well as increased ethanol drinking behaviors. We found that acamprosate significantly reduced ethanol drinking of mice lacking ENT1 (ENT1 -/-) while having no such effect in wild-type littermates. We then analyzed the basal and acamprosate-treated accumbal metabolite profiles of ENT1 -/- and wild-type mice using in vivo 16.4T proton magnetic resonance spectroscopy (MRS). Our data show that basal glutamate+glutamine (Glx), glutamate, glutamine and N-acetylaspartatic acid (NAA) levels are increased in the nucleus accumbens (NAc) of ENT1 -/- compared to wild-type mice. We then found that acamprosate treatment significantly reduced Glx and glutamine levels while increasing taurine levels in the NAc of only ENT1 -/- compared to their saline-treated group while normalizing other metabolite compared to wild-type mice. This study will be useful in the understanding of the molecular basis of acamprosate in the brain.",
keywords = "Acamprosate, Alcoholism, ENT1, Glutamate, In vivo MRS, Taurine",
author = "Lee, {Moonnoh R.} and Hinton, {David J.} and Jinhua Wu and Mishra, {Prasanna K.} and Port, {John D} and Macura, {Slobodan I} and Choi, {Doo Sup}",
year = "2011",
month = "2",
day = "25",
doi = "10.1016/j.neulet.2010.12.033",
language = "English (US)",
volume = "490",
pages = "90--95",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1

AU - Lee, Moonnoh R.

AU - Hinton, David J.

AU - Wu, Jinhua

AU - Mishra, Prasanna K.

AU - Port, John D

AU - Macura, Slobodan I

AU - Choi, Doo Sup

PY - 2011/2/25

Y1 - 2011/2/25

N2 - Acamprosate is clinically used to treat alcoholism. However, the precise molecular functionality of acamprosate in the central nervous system remains unclear, although it is known to antagonize glutamate action in the brain. Since elevated glutamate signaling, especially in the nucleus accumbens (NAc), is implicated in several aspects of alcoholism, we utilized mice lacking type 1 equilibrative nucleoside transporter (ENT1), which exhibit increased glutamate levels in the NAc as well as increased ethanol drinking behaviors. We found that acamprosate significantly reduced ethanol drinking of mice lacking ENT1 (ENT1 -/-) while having no such effect in wild-type littermates. We then analyzed the basal and acamprosate-treated accumbal metabolite profiles of ENT1 -/- and wild-type mice using in vivo 16.4T proton magnetic resonance spectroscopy (MRS). Our data show that basal glutamate+glutamine (Glx), glutamate, glutamine and N-acetylaspartatic acid (NAA) levels are increased in the nucleus accumbens (NAc) of ENT1 -/- compared to wild-type mice. We then found that acamprosate treatment significantly reduced Glx and glutamine levels while increasing taurine levels in the NAc of only ENT1 -/- compared to their saline-treated group while normalizing other metabolite compared to wild-type mice. This study will be useful in the understanding of the molecular basis of acamprosate in the brain.

AB - Acamprosate is clinically used to treat alcoholism. However, the precise molecular functionality of acamprosate in the central nervous system remains unclear, although it is known to antagonize glutamate action in the brain. Since elevated glutamate signaling, especially in the nucleus accumbens (NAc), is implicated in several aspects of alcoholism, we utilized mice lacking type 1 equilibrative nucleoside transporter (ENT1), which exhibit increased glutamate levels in the NAc as well as increased ethanol drinking behaviors. We found that acamprosate significantly reduced ethanol drinking of mice lacking ENT1 (ENT1 -/-) while having no such effect in wild-type littermates. We then analyzed the basal and acamprosate-treated accumbal metabolite profiles of ENT1 -/- and wild-type mice using in vivo 16.4T proton magnetic resonance spectroscopy (MRS). Our data show that basal glutamate+glutamine (Glx), glutamate, glutamine and N-acetylaspartatic acid (NAA) levels are increased in the nucleus accumbens (NAc) of ENT1 -/- compared to wild-type mice. We then found that acamprosate treatment significantly reduced Glx and glutamine levels while increasing taurine levels in the NAc of only ENT1 -/- compared to their saline-treated group while normalizing other metabolite compared to wild-type mice. This study will be useful in the understanding of the molecular basis of acamprosate in the brain.

KW - Acamprosate

KW - Alcoholism

KW - ENT1

KW - Glutamate

KW - In vivo MRS

KW - Taurine

UR - http://www.scopus.com/inward/record.url?scp=79451471915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79451471915&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2010.12.033

DO - 10.1016/j.neulet.2010.12.033

M3 - Article

VL - 490

SP - 90

EP - 95

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -